HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $19 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioLine Rx (NASDAQ:BLRX) and maintained a $19 price target.

August 31, 2023 | 8:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioLine Rx's stock may see positive movement due to the reiterated 'Buy' rating and maintained $19 price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence the stock price. A 'Buy' rating suggests that the analyst believes the stock will outperform the market, which can lead to increased investor interest and a potential rise in stock price. The maintained $19 price target indicates that the analyst believes the stock is undervalued at its current price, which can also attract investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100